Latest Orphazyme stock drops after receiving CRL from FDA after NPC treatment review [ad_1] Shares of Orphazyme A/S ORPH, -41.21%, fell 54.3% in premarket trading Friday, after the Denmark-based biopharmaceutical company… bynewsdeskJune 18, 2021
